Drugs / Pembrolizumab injection
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05266846 Background | May 2024 → Nov 2026 expected | lung adenocarcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05266846 ↗ |